HOME › DRUGS › UPADACITINIB
ACTIVE SUBSTANCE / INN

UPADACITINIB

Brand name(s): RINVOQ LQ, RINVOQ, Rinvoq, UPADACITINIB
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
NONE (TENTATIVE APPROVAL)
Arthritis, Rheumatoid
ANDA218866
ACTIVE SUBSTANCE
Upadacitinib
REGULATORS
FDA · EMA
SPONSORS / MAH
AbbVie Deutschland GmbH & Co. KG, AUROBINDO PHARMA LTD, ABBVIE
TOTAL APPLICATIONS
4
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
UPADACITINIBANDA218866AUROBINDO PHARMA LTDNone (Tentative Approval)
RINVOQNDA211675ABBVIEPrescription
RINVOQ LQNDA218347ABBVIEPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
RinvoqAbbVie Deutschland GmbH & Co. KGAuthorised16/12/2019Arthritis, Rheumatoid

FULL INTELLIGENCE ON UPADACITINIB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →